Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723801 · ClinicalTrials.gov registry record · Phase 3
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
A Phase 3 study of Marfan Syndrome, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00723801 is a Phase 3 study of Marfan Syndrome that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 40 participants, below the 393-participant average among 4 other Marfan Syndrome trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00723801, a Phase 3 study of Marfan Syndrome, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Marfan syndrome is an inherited connective tissue disorder with morbidity and mortality from aortic dilation and dissection. The degree of aortic dilation and response to beta-blockade (standard of care) vary in adults with Marfan syndrome. However, aortic stiffness is often present, and can be a predictor of aortic dilation and cardiovascular complications. In addition, adults with Marfan syndrome develop left ventricular diastolic dysfunction, which can progress to heart failure. Aortic stiffness and diastolic dysfunction are important and logical therapeutic targets in adults with Marfan syndrome. TGF-beta mediates disease pathogenesis in Marfan syndrome and contributes to aortic stiffness. The angiotensin receptor blocker, losartan, inhibits TGF-beta activity and reverses aortic wall pathology in a Marfan mouse model. Losartan also decreases aortic stiffness and improves diastolic function in hypertension, renal disease and hypertrophic cardiomyopathy. This trial is a randomized, double-blind trial of 50 adults with Marfan syndrome, treated with 6 months of atenolol vs. losartan. Arterial tonometry for aortic stiffness and echocardiography for diastolic function will be performed at the beginning and end of treatment. A blood draw for serum markers of extracellular matrix turnover and inflammation will also be performed at 0 and 6 months. We plan to determine whether losartan decreases aortic stiffness and left ventricular diastolic dysfunction significantly more than atenolol.
Conditions Studied
Interventions
- DRUG Losartan
- DRUG Atenolol
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723801
The ClinicalTrials.gov registry entry for NCT00723801 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 4 other Marfan Syndrome trials with a reported enrollment target (90% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Marfan Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Losartan is the first listed.
NCT00723801 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00723801 about?
NCT00723801 is a clinical study titled "Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome". Marfan syndrome is an inherited connective tissue disorder with morbidity and mortality from aortic dilation and dissection. The degree of aortic dilation and response to beta-blockade (standard of care) vary in adults with Marfan syndrome. However, aortic stiffness is often present, and can be a pr...
What is the current status of trial NCT00723801?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2007-10. Estimated completion is 2012-12.
What conditions does trial NCT00723801 study?
This clinical trial studies the following conditions: Marfan Syndrome.
What interventions are being tested in trial NCT00723801?
The interventions under investigation include: Losartan (DRUG), Atenolol (DRUG).
Who is sponsoring clinical trial NCT00723801?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00723801 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marfan Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Marfan Syndrome Moderate Exercise Trial II
RECRUITING · NA
-
Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices
RECRUITING · NA
-
Study of Heritable Connective Tissue Disorders
COMPLETED
-
Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.